SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

Simple item page
dc.contributor.authorAguilera, Ximena
dc.contributor.authorHormazábal, Juan
dc.contributor.authorVial, Cecilia
dc.contributor.authorCortés, Lina Jimena
dc.contributor.authorGonzález, Claudia
dc.contributor.authorRubilar, Paola
dc.contributor.authorApablaza, Mauricio
dc.contributor.authorRamírez-Santana, Muriel
dc.contributor.authorIcaza, Gloria
dc.contributor.authorNúñez-Franz, Loreto
dc.contributor.authorCastillo-Laborde, Carla
dc.contributor.authorRamírez-Riffo, Carolina
dc.contributor.authorPérez, Claudia
dc.contributor.authorQuezada-Gate, Rubén
dc.contributor.authorSaid, Macarena
dc.contributor.authorVial, Pablo
dc.date.accessioned2023-04-27T17:58:06Z
dc.date.available2023-04-27T17:58:06Z
dc.date.issued2022
dc.description.abstractUsing levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.
dc.description.versionVersión publicada
dc.format.extent7 p.
dc.identifier.citationAguilera, X.; Hormazábal, J.; Vial, C.; Cortes, L.J.; González, C.; Rubilar, P.; Apablaza, M.; Ramírez-Santana, M.; Icaza, G.; Nuñez-Franz, L.; et al. SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes. Vaccines 2022, 10, 1051. https://doi.org/10.3390/ vaccines10071051
dc.identifier.doihttps://doi.org/10.3390/vaccines10071051
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7421
dc.language.isoen
dc.subjectneutralizing antibodies; vaccines; BNT162b2; CoronaVac; AZD1222; COVID-19; SARS-CoV-2; cross-sectional design; vaccine-preventable diseases; viruses
dc.subjectVaccines
dc.subjectBNT162b2
dc.subjectCoronaVac
dc.subjectAZD1222
dc.subjectCovid-19
dc.subjectSars-CoV-2
dc.subjectCross-sectional design
dc.subjectVaccine-preventable diseases
dc.subjectViruses
dc.titleSARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceVaccines

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
SARS_CoV_2_neutralizing_antibodies_in_Ch.pdf
Size:
559.42 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Gobierno

Implementado por OpenGeek Services